Cannabix Technologies and Omega Laboratories Announce Breath-Based DOT-Like Drug Testing Panel for Recent-Use Detection

Vancouver, British Columbia, July 8, 2026 -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) and Omega Laboratories, Inc. (“Omega”) announce the development and validation of a DOT-like drug-test panel for breath testing. The validated laboratory method expands Omega’s breath-testing capability beyond cannabinoids and enables simultaneous detection of multiple drug classes in breath aerosols collected using Cannabix Technologies’ Breath Collection Unit.

The panel is modeled after the drug classes included in the DOT federally mandated urine drug test panel which includes amphetamines/methamphetamines, cocaine, marijuana, opiates and PCP. By validating these drug classes in breath, Omega is advancing a testing option designed to help employers, courts, criminal justice programs, treatment and recovery organizations, schools, and other safety-sensitive environments focus on recent drug use rather than historical use.

While marijuana legalization has accelerated demand for testing methods that can better distinguish recent use from historical use, safety-sensitive programs also need a practical way to determine whether drugs beyond marijuana are a concern. By expanding breath testing beyond cannabinoids to a broader DOT-like drug panel, Omega’s method is designed to help decision-makers evaluate recent use across multiple drug classes in situations where timing, safety, and defensibility are critical.

Traditional drug testing matrices often identify use over longer detection windows. Oral fluid may detect use for one to two days, urine may detect certain drugs for several days, and hair may reflect drug use over a period of months. Breath testing is intended to address a more immediate window of detection, generally minutes to hours after use, making it particularly relevant for reasonable suspicion, random, post-incident, forensic, evidentiary, and other safety-sensitive testing scenarios.

“This is an important milestone for breath testing and for organizations that need a more time-relevant tool for drug testing,” said Bill Corl, CEO of Omega Laboratories. “A DOT-like panel in breath gives customers a practical path to focus on recent use while maintaining the forensic quality, laboratory confirmation, and defensibility they expect from Omega.”

Omega’s laboratory-based breath testing is performed using mass spectrometry, a gold-standard analytical approach for confirming the presence of targeted analytes. The Cannabix Breath Collection Unit and Breath Cartridge system are designed to support observed, non-invasive collection and include safeguards such as a start-up airflow self-check, ambient air collection to help rule out environmental contamination, and split A/B sample collection to support confirmatory workflows.

Although many testing programs are interested in rapid onsite results, Omega’s current breath test is intentionally laboratory-based to support the level of analytical sensitivity, confirmation, chain-of-custody integrity, and defensibility required in safety-sensitive, forensic, workplace, and criminal justice settings. The laboratory-based model allows breath testing to be positioned not as a presumptive screen, but as a scientifically supported recent-use testing option backed by mass spectrometry and Omega’s established toxicology infrastructure.

The announcement builds on Omega’s peer-reviewed work with Cannabix in the Journal of Analytical Toxicology, which validated Omega’s laboratory method for the simultaneous analysis of Δ9-THC, Δ8-THC, CBD, and CBN in breath aerosols collected using the Cannabix Technologies Breath Collection Unit. Together, the published cannabinoid validation and the expanded DOT-like panel validation reinforce Omega’s commitment to developing reliable, defensible, and scientifically supported breath-testing solutions.

Omega’s current THC breath test and expanded DOT-like panel are available to existing and new clients. The company expects breath testing to be especially relevant in settings where decision-makers need to understand whether drug use was recent, while avoiding overreliance on testing methods that may primarily reflect past use. Omega believes laboratory-based breath testing may become an important complement to existing drug-testing matrices as employers and other safety-sensitive programs seek more time-relevant, scientifically defensible testing options.